Mulighed for aendring af ordinationsmønster

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Mulighed for aendring af ordinationsmønster. / Reuther, Lene Ørskov; Christensen, Hanne Rolighed; Mikkelsen, Camilla.

In: Ugeskrift for læger, Vol. 171, No. 37, 2009, p. 2655-6.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Reuther, LØ, Christensen, HR & Mikkelsen, C 2009, 'Mulighed for aendring af ordinationsmønster', Ugeskrift for læger, vol. 171, no. 37, pp. 2655-6.

APA

Reuther, L. Ø., Christensen, H. R., & Mikkelsen, C. (2009). Mulighed for aendring af ordinationsmønster. Ugeskrift for læger, 171(37), 2655-6.

Vancouver

Reuther LØ, Christensen HR, Mikkelsen C. Mulighed for aendring af ordinationsmønster. Ugeskrift for læger. 2009;171(37):2655-6.

Author

Reuther, Lene Ørskov ; Christensen, Hanne Rolighed ; Mikkelsen, Camilla. / Mulighed for aendring af ordinationsmønster. In: Ugeskrift for læger. 2009 ; Vol. 171, No. 37. pp. 2655-6.

Bibtex

@article{73a8a28088d411df928f000ea68e967b,
title = "Mulighed for aendring af ordinationsm{\o}nster",
abstract = "In 2005 the Central Drug Committee in co-operation with the hospitals in the county of Copenhagen (H:S) focused on the increasing use of and expenditure derived from three tumour necrosis factor alpha (TNF-alpha) inhibitors. While the three inhibitors are estimated to be equivalent regarding efficacy and safety, eternacept and adalimumab are twice as expensive as infliximab. With a little effort, the Central Drug Committee succeeded in changing clinicians' prescription pattern in a cost-effective manner. Udgivelsesdato: 2009-Sep",
author = "Reuther, {Lene {\O}rskov} and Christensen, {Hanne Rolighed} and Camilla Mikkelsen",
note = "Keywords: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Denmark; Drug Costs; Humans; Immunoglobulin G; Physician's Practice Patterns; Practice Guidelines as Topic; Receptors, Tumor Necrosis Factor; Therapeutic Equivalency",
year = "2009",
language = "Dansk",
volume = "171",
pages = "2655--6",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "37",

}

RIS

TY - JOUR

T1 - Mulighed for aendring af ordinationsmønster

AU - Reuther, Lene Ørskov

AU - Christensen, Hanne Rolighed

AU - Mikkelsen, Camilla

N1 - Keywords: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Denmark; Drug Costs; Humans; Immunoglobulin G; Physician's Practice Patterns; Practice Guidelines as Topic; Receptors, Tumor Necrosis Factor; Therapeutic Equivalency

PY - 2009

Y1 - 2009

N2 - In 2005 the Central Drug Committee in co-operation with the hospitals in the county of Copenhagen (H:S) focused on the increasing use of and expenditure derived from three tumour necrosis factor alpha (TNF-alpha) inhibitors. While the three inhibitors are estimated to be equivalent regarding efficacy and safety, eternacept and adalimumab are twice as expensive as infliximab. With a little effort, the Central Drug Committee succeeded in changing clinicians' prescription pattern in a cost-effective manner. Udgivelsesdato: 2009-Sep

AB - In 2005 the Central Drug Committee in co-operation with the hospitals in the county of Copenhagen (H:S) focused on the increasing use of and expenditure derived from three tumour necrosis factor alpha (TNF-alpha) inhibitors. While the three inhibitors are estimated to be equivalent regarding efficacy and safety, eternacept and adalimumab are twice as expensive as infliximab. With a little effort, the Central Drug Committee succeeded in changing clinicians' prescription pattern in a cost-effective manner. Udgivelsesdato: 2009-Sep

M3 - Tidsskriftartikel

C2 - 19758512

VL - 171

SP - 2655

EP - 2656

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 37

ER -

ID: 20649539